While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

In this segment, Dr Luskin examines how patient-related factors influence treatment decisions in blastic plasmacytoid ...

Leyla O. Shune, MD, describes the available treatment options for patients with chronic graft-versus-host disease who are ...

Final results from the phase 3 CASSANDRA trial presented at the 2025 ASCO Meeting show that the neoadjuvant chemotherapy ...

Dr Benjamin George champions innovative oncology care in rural Nebraska, emphasizing collaboration and multidisciplinary ...

Dr Benjamin George transforms oncology care in rural Nebraska, addressing unique challenges and enhancing access to vital ...

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.

Luveltamab tazevibulin, a novel ADC, showed encouraging responses in platinum-resistant ovarian cancer, with a 32% ORR and a ...

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized treatment for hematologic malignancies, butacquired BTK mutations often ...

Dr Benjamin George champions accessible cancer care in rural Nebraska, transforming patient support with innovative programs ...

Marija Balic, MD, discusses the design and mechanism of the Oncodetect tumor-informed circulating tumor DNA assay for ...